EUVIMEDEUVIMED entdecken
Crossref

TRPA1 siRNA-Loaded Nanoformulation Ameliorates Chemotherapy-Induced Peripheral Neuropathy

Akhilesh, Anurag Kumar Singh iD, Vinod Tiwari iD

ACS Chemical Neuroscience · 04.06.2025 · 16 (11) · 2060-2075

DOI: 10.1021/acschemneuro.5c00090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 27.05.2025. Verfasst von Akhilesh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience and Pain Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, UP …. Hauptthemen laut MEDLINE: TRPA1 Cation Channel, RNA, Small Interfering, Neuralgia, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Indian Council of Medical Research, Science and Engineering Research Board, Council of Science and Technology, U.P..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small interfering RNA (siRNA) has emerged as a cutting-edge therapeutic strategy, with significant promise for addressing peripheral neuropathies. Despite its immense revolutionary therapeutic potential, the application and sustained release of siRNA for the treatment of chronic pain remain an arduous scientific challenge. This study introduces a novel cationic lipid-based siRNA formulation specifically targeting transient receptor potential ankyrin 1 (TRPA1) for the systemic treatment of chemotherapy-induced neuropathic pain (CINP), a condition with no US-FDA-approved therapeutic options. CINP involves the upregulation of the TRPA1 channel, a key player in nociceptive signaling. Our approach leverages the selective silencing of the TRPA1 gene via siRNA encapsulated in liposomes, offering a targeted and safer therapeutic intervention. The proof-of-principle was established through in vivo experiments, demonstrating significant downregulation of TRPA1 mRNA and protein expressions in the spinal cord following intrathecal administration. Liposomal encapsulation improved siRNA stability and delivery, validated through sophisticated morphometric and analytical techniques. Behavioral assays revealed that both intravenous and intrathecal administrations of this TRPA1 siRNA formulation significantly reduced mechanical and cold hypersensitivity in CINP models. The sustained release profile of siRNA from liposomes ensured prolonged efficacy, contrasting sharply with the transient effects of nonencapsulated siRNA. Mechanistically, silencing of the TRPA1 gene led to decreased microglial activation and reduced expression of inflammatory markers such as ICAM-1 and iba1, mitigating neuroinflammatory responses in the dorsal root ganglia and spinal cord. Intravenous delivery notably outperformed intrathecal administration in downregulating TRPA1 and IL-6 expressions. Overall findings highlight the potential of this nanoengineered TRPA1 siRNA formulation to effectively modulate critical inflammatory pathways and manage CINP. This innovative and exciting strategy not only overcomes the limitations of conventional therapies but also paves the way for new approaches in chronic pain management with significant implications for future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPA1 Cation ChannelRNA, Small InterferingNeuralgiaAntineoplastic AgentsPeripheral Nervous System DiseasesAnimalsMaleLiposomesMiceRatsSpinal CordRats, Sprague-Dawley

Stichwörter der Autor:innen

TRPA1 silencingchemotherapyinflammatory modulationliposomal deliveryneuropathic painsiRNA

Substanzen

TRPA1 Cation ChannelRNA, Small InterferingLiposomesAntineoplastic Agents

Autor:innen und Institutionen

  • Neuroscience and Pain Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, UP India, 221005.

ORCID-Profile: Anurag Kumar Singh, Vinod Tiwari

Förderung

  • Indian Council of Medical Research
  • Science and Engineering Research Board
  • Council of Science and Technology, U.P.

Zitieren

APA

Akhilesh, Singh, A. K., & Tiwari, V. (2025). TRPA1 siRNA-Loaded Nanoformulation Ameliorates Chemotherapy-Induced Peripheral Neuropathy. ACS Chemical Neuroscience, 16(11), 2060-2075. https://doi.org/10.1021/acschemneuro.5c00090

Vancouver

Akhilesh, Singh AK, Tiwari V. TRPA1 siRNA-Loaded Nanoformulation Ameliorates Chemotherapy-Induced Peripheral Neuropathy. ACS Chemical Neuroscience. 2025;16(11):2060-2075. doi:10.1021/acschemneuro.5c00090

BibTeX
@article{Akhilesh2025,
  author = {Akhilesh and Singh, Anurag Kumar and Tiwari, Vinod},
  title = {TRPA1 siRNA-Loaded Nanoformulation Ameliorates Chemotherapy-Induced Peripheral Neuropathy},
  journal = {ACS Chemical Neuroscience},
  year = {2025},
  volume = {16},
  number = {11},
  pages = {2060--2075},
  doi = {10.1021/acschemneuro.5c00090}
}
Kostenlos starten →